New Pill-and-Antibody combo may replace chemo for common lymphoma
NCT ID NCT01650701
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a combination of two drugs (rituximab and lenalidomide) works better than standard chemotherapy plus rituximab for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,030 adults with advanced disease who needed treatment took part. The goal was to see if the new combo could control the disease longer and improve response rates without the side effects of chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health Sciences Corp - Saint John Regional Hospital
Halifax, Nova Scotia, Canada
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
-
CHU Claude Huriez
Lille, France
-
CHU Mont-Godinne
Yvoir, Belgium
-
CHUM Hopital Notre-Dame
Montreal, Quebec, Canada
-
Concord Repatriation General Hospital
Concord, New South Wales, Australia
-
Cross Cancer Institute
Edmonton, Alberta, Canada
-
Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
-
Hospital Clínico Universitario de Valencia
Valencia, Spain
-
Hospital Clínico de Barcelona
Barcelona, Spain
-
Hospital Costa del Sol
Marbella, Spain
-
Hospital Ramon y Cajal
Madrid, Spain
-
Hospital Son Llatzer
Palma, Mallorca, Spain
-
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, Spain
-
Hospital Universitario Salamanca
Salamanca, Spain
-
Hospital Universitario Vall d´Hebron
Barcelona, Spain
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canary Islands, Spain
-
Hospital Virgen del Rocio
Seville, Andaloucia, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
Hôpital de l'Enfant-Jesus, CHU de Quebec
Québec, Quebec, Canada
-
Institut Català d'Oncologia de Girona (ICO Girona)
Girona, Spain
-
Instituto Português Oncologia
Lisbon, Portugal
-
LMU Munchën - Klinikum Grosshadern
München, Germany
-
McGill University Department of Oncology
Montreal, Quebec, Canada
-
Medizinische Klinik der Universität Tübingen
Tübingen, Baden-Wurttemberg, Germany
-
Moncton Hospital
Moncton, New Brunswick, Canada
-
Nepean Hospital
Penrith, New South Wales, Australia
-
Policlinico Sant'Orsola-Malpighi
Bologna, Italy
-
Sant'Andrea Hospital
Rome, Lazio, Italy
-
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, Canada
-
UHN-Princess Margaret Hospital
Toronto, Ontario, Canada
-
Uniklinik Köln
Cologne, Nordrhein, Germany
-
Wollongong Hospital
Wollongong, New South Wales, Australia